- Home
- CLPR vs MRSN Comparison
CLPR vs MRSN Comparison
Compare CLPR & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLPR
- MRSN
- Stock Information
- Founded
- CLPR 2015
- MRSN 2001
- Country
- CLPR United States
- MRSN United States
- Employees
- CLPR N/A
- MRSN N/A
- Industry
- CLPR Real Estate Investment Trusts
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- CLPR Real Estate
- MRSN Health Care
- Exchange
- CLPR Nasdaq
- MRSN Nasdaq
- Market Cap
- CLPR 77.0M
- MRSN 74.8M
- IPO Year
- CLPR 2017
- MRSN 2017
- Fundamental
- Price
- CLPR $4.08
- MRSN $0.61
- Analyst Decision
- CLPR Sell
- MRSN Buy
- Analyst Count
- CLPR 2
- MRSN 6
- Target Price
- CLPR N/A
- MRSN $6.00
- AVG Volume (30 Days)
- CLPR 98.8K
- MRSN 9.7M
- Earning Date
- CLPR 03-13-2025
- MRSN 02-26-2025
- Dividend Yield
- CLPR 9.59%
- MRSN N/A
- EPS Growth
- CLPR N/A
- MRSN N/A
- EPS
- CLPR N/A
- MRSN N/A
- Revenue
- CLPR $145,595,000.00
- MRSN $34,837,000.00
- Revenue This Year
- CLPR N/A
- MRSN N/A
- Revenue Next Year
- CLPR N/A
- MRSN N/A
- P/E Ratio
- CLPR N/A
- MRSN N/A
- Revenue Growth
- CLPR 6.78
- MRSN N/A
- 52 Week Low
- CLPR $3.38
- MRSN $0.49
- 52 Week High
- CLPR $7.12
- MRSN $6.28
- Technical
- Relative Strength Index (RSI)
- CLPR 43.74
- MRSN 31.86
- Support Level
- CLPR $3.92
- MRSN $0.58
- Resistance Level
- CLPR $4.18
- MRSN $0.69
- Average True Range (ATR)
- CLPR 0.24
- MRSN 0.08
- MACD
- CLPR 0.05
- MRSN 0.04
- Stochastic Oscillator
- CLPR 43.75
- MRSN 49.52
About CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. Clipper derives its revenue mostly from a Residential segment.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.